IVI Increases its Investment in Research to 6 Million

Research is the key to development. The Valencian Fertility Institute (IVI RMA) has raised its investment in research to €6 million, which means quadrupling the figure reached five years ago, as explained by Nicolás Garrido, director of the IVI Foundation.

The head of the company specializing in assisted reproduction comments that the group currently has 400 active research projects, initiatives that are supervised by a scientific committee made up of Juan García, chief scientific officer of IVI RMA; Nicolás Garrido; Antonio Pellicer, CEO of the company; Richard Scott, founding partner of IVI RMA; Emre Seli, director of research in the United States; and Dagan Wells, director of research in Oxford.

Garrido comments that one of the main lines of research in which the group is working is that of advanced age and ovarian rejuvenation. The scientific team at IVI RMA focuses its research on identifying new treatment strategies that can activate primordial follicles in patients with advanced reproductive aging.

Read more on the subject and find other important business headlines with our companion app Born2Invest.

IVI RMA is working on defining methylation profiles with respect to gametes and embryos prior to implantation

Another line of research concerns male infertility. The male factor is one of those responsible for fertility problems in 20% of couples and contributes in 30% to 40% of cases, according to IVI RMA.

IVIR MA researchers are also designing strategies to define methylation profiles with respect to gametes and embryos prior to implantation, with the aim of identifying abnormalities associated with failures in embryo generation and during implantation. In addition, the professionals are conducting projects to determine methylation levels in somatic cells and identify early and subtle signs of reproductive aging.

The company’s scientific team has launched several studies in different fields of reproduction using stem cells. The first data obtained in a prospective study of patients with Asherman’s syndrome (with a severely damaged uterine cavity) or endometrial atrophy (problems during endometrial growth) suggest that endometrial growth can be improved and tissue damage reduced by transplanting stem cells from bone marrow.

The company had a turnover of more than €380 million in 2021, raising turnover by 36% compared to 2020

Each of the clinics that make up IVI RMA’s worldwide network (more than 65 clinics) is likely to pursue one or more of the lines of research currently open within the group. However, there are several specific locations for research such as Basking Ridge (New Jersey, USA), Madrid, Valencia, and Oxford.

The fertility multinational increased its turnover by more than 36% in 2021 compared to 2020, to €387 million. The company also raised its profit by more than 16% in the last year, to €56 million.

__

(Featured image by felixioncool via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.